← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #903 OF 1,000 MOST-CITED

Documentation - review in response to changes or deviations

FDA cited this observation 16 times across 16 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Devices16
BY FISCAL YEAR
FY20242
FY20231
FY20211
FY20201
FY20193
FY20185
FY20173

How FDA worded it — real examples

There is no documentation of the review and evaluation of a process and revalidation of a process performed in response to changes or process deviations.

Hupfer Metallwerke GmbH & Co. KG · Coesfeld · Devices · 2024-08-29

There is no documentation of the revalidation of a process performed in response to changes or process deviations.

Rapid Oxygen Inc. · Shelton, Connecticut · Devices · 2024-04-26

There is no documentation of the revalidation of a process performed in response to changes or process deviations.

Frantz Medical Development Ltd · Mentor, Ohio · Devices · 2023-06-27

There is no documentation of the review and evaluation of a process performed in response to changes or process deviations.

BSN Medical Inc · Charlotte, North Carolina · Devices · 2021-03-22

There is no documentation of the review and evaluation of a process performed in response to changes or process deviations.

American Contract Systems, Inc. · Houston, Texas · Devices · 2019-10-04

There is no documentation of the review and evaluation of a process performed in response to changes or process deviations.

SIAM STERI SERVICES CO., LTD · Phan Thong · Devices · 2019-08-23

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Data integrity (ALCOA+)Medical devices

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →